Related content

A Multicenter Evaluation of the Safety of Drotrecogin Alfa (Activated) in Patients with Baseline Bleeding Precautions

By  

Current Drug Safety, Vol. 7, Iss. 1, 2012-02 ,pp. : 3-7

Bentham Science Publishers

Access to resources Recommend Favorite

International integrated database for the evaluation of severe sepsis (INDEPTH): clinical evaluation committee report on the safety of drotrecogin alfa (activated) therapy

By Dhainaut Jean-François    

Current Medical Research and Opinion, Vol. 24, Iss. 4, 2008-04 ,pp. : 1187-1197

Informa Healthcare

Access to resources Recommend Favorite

Comparison of mechanisms after post-hoc analyses of the drotrecogin alfa (activated) and antithrombin III trials in severe sepsis

By Wiedermann Christian   Kaneider Nicole  

Annals of Medicine, Vol. 36, Iss. 3, 2004-05 ,pp. : 194-203

Informa Healthcare

Access to resources Recommend Favorite

When a single pivotal trial should not be enough–the case of drotrecogin-alfa (activated)

By Wiedermann Christian  

Intensive Care Medicine, Vol. 32, Iss. 4, 2006-04 ,pp. : 604-604

Springer Publishing Company

Access to resources Recommend Favorite

Timing of drotrecogin alfa (activated) initiation in treatment of severe sepsis: a database cohort study of hospital mortality, length of stay, and costs

By Ernst F. R.   Johnston J. A.   Pulgar S.   He J.   Ball D. E.   Young J. K.   Cooper L. M.  

Current Medical Research and Opinion, Vol. 23, Iss. 1, 2007-01 ,pp. : 235-244

Informa Healthcare

Access to resources Recommend Favorite